title: Dyslipidaemia in 2015: Advances in treatment of dyslipidaemia.
authors.affiliation: Center for Human Nutrition and Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Suite Y3.206, Dallas, Texas 75390-9052, USA.
authors.forename: Scott M
authors.initials: SM
authors.lastname: Grundy
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects*; D050171:Dyslipidemias / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D020719:Glucuronides / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy; D015201:Meta-Analysis as Topic; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors*; D016032:Randomized Controlled Trials as Topic; D012697:Serine Endopeptidases; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D015415:Biomarkers; D008078:Cholesterol, LDL; D020719:Glucuronides; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C511436:ezetimibe glucuronide; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases